Novartis Ag Adr Stock Working Capital

NVS Stock  USD 95.88  0.61  0.64%   
Novartis AG ADR fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Stock. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis stock.
Net Working Capital is likely to gain to about 5.7 B in 2024, despite the fact that Change In Working Capital is likely to grow to (350.6 M).
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novartis Working Capital Analysis

Novartis' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

 = 

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Novartis Working Capital

    
  4.09 B  
Most of Novartis' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novartis Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Novartis is extremely important. It helps to project a fair market value of Novartis Stock properly, considering its historical fundamentals such as Working Capital. Since Novartis' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novartis' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novartis' interrelated accounts and indicators.
0.660.920.520.710.920.920.7-0.01-0.050.00.880.410.55-0.070.930.750.610.760.98-0.010.830.10.370.26-0.360.190.290.260.040.22
0.660.360.040.70.390.740.260.390.16-0.660.860.750.61-0.440.720.360.240.810.640.510.35-0.490.27-0.35-0.420.60.3-0.290.11-0.1
0.920.360.650.430.990.830.71-0.08-0.060.310.620.260.280.120.770.620.520.470.92-0.260.880.420.250.38-0.27-0.140.170.450.180.29
0.520.040.650.120.690.350.23-0.26-0.210.330.260.04-0.070.10.330.550.410.280.47-0.290.440.460.210.5-0.72-0.160.030.310.10.2
0.710.70.430.120.490.610.450.14-0.14-0.40.880.230.62-0.250.850.730.460.910.680.320.35-0.430.360.15-0.290.580.24-0.05-0.180.09
0.920.390.990.690.490.820.7-0.05-0.120.240.650.270.270.060.80.680.560.540.92-0.180.840.380.310.38-0.36-0.070.20.40.20.27
0.920.740.830.350.610.820.65-0.010.14-0.10.840.430.49-0.120.870.580.360.660.94-0.010.87-0.010.180.09-0.280.140.150.070.020.15
0.70.260.710.230.450.70.65-0.28-0.50.290.530.040.29-0.030.690.460.370.440.77-0.280.80.230.270.210.060.030.110.18-0.030.1
-0.010.39-0.08-0.260.14-0.05-0.01-0.280.22-0.50.080.67-0.06-0.120.08-0.29-0.160.17-0.030.51-0.35-0.160.05-0.53-0.010.20.240.010.76-0.01
-0.050.16-0.06-0.21-0.14-0.120.14-0.50.22-0.21-0.020.190.090.09-0.11-0.2-0.2-0.22-0.080.12-0.03-0.16-0.25-0.170.13-0.18-0.03-0.01-0.010.05
0.0-0.660.310.33-0.40.24-0.10.29-0.5-0.21-0.36-0.54-0.290.74-0.16-0.020.07-0.480.05-0.830.30.85-0.150.650.39-0.77-0.330.75-0.130.54
0.880.860.620.260.880.650.840.530.08-0.02-0.360.490.75-0.270.920.740.590.930.850.280.59-0.290.430.08-0.390.530.37-0.02-0.120.1
0.410.750.260.040.230.270.430.040.670.19-0.540.490.36-0.380.36-0.020.230.480.360.530.11-0.150.35-0.57-0.340.420.51-0.120.58-0.16
0.550.610.28-0.070.620.270.490.29-0.060.09-0.290.750.36-0.250.620.530.630.620.490.360.29-0.350.59-0.04-0.060.520.510.0-0.360.01
-0.07-0.440.120.1-0.250.06-0.12-0.03-0.120.090.74-0.27-0.38-0.25-0.19-0.11-0.03-0.39-0.05-0.750.030.72-0.360.670.48-0.77-0.370.84-0.110.9
0.930.720.770.330.850.80.870.690.08-0.11-0.160.920.360.62-0.190.760.520.830.930.150.69-0.120.420.13-0.310.330.30.110.020.13
0.750.360.620.550.730.680.580.46-0.29-0.2-0.020.74-0.020.53-0.110.760.760.740.680.090.52-0.040.50.52-0.470.320.320.15-0.290.18
0.610.240.520.410.460.560.360.37-0.16-0.20.070.590.230.63-0.030.520.760.580.50.120.350.20.790.41-0.260.330.70.35-0.10.22
0.760.810.470.280.910.540.660.440.17-0.22-0.480.930.480.62-0.390.830.740.580.710.420.38-0.360.510.04-0.530.710.41-0.13-0.040.0
0.980.640.920.470.680.920.940.77-0.03-0.080.050.850.360.49-0.050.930.680.50.71-0.060.870.120.30.22-0.290.110.180.240.040.22
-0.010.51-0.26-0.290.32-0.18-0.01-0.280.510.12-0.830.280.530.36-0.750.150.090.120.42-0.06-0.32-0.710.4-0.63-0.310.760.39-0.580.2-0.56
0.830.350.880.440.350.840.870.8-0.35-0.030.30.590.110.290.030.690.520.350.380.87-0.320.270.070.31-0.12-0.11-0.010.22-0.090.14
0.1-0.490.420.46-0.430.38-0.010.23-0.16-0.160.85-0.29-0.15-0.350.72-0.12-0.040.2-0.360.12-0.710.270.00.520.2-0.74-0.050.80.280.6
0.370.270.250.210.360.310.180.270.05-0.25-0.150.430.350.59-0.360.420.50.790.510.30.40.070.0-0.06-0.270.50.810.040.1-0.12
0.26-0.350.380.50.150.380.090.21-0.53-0.170.650.08-0.57-0.040.670.130.520.410.040.22-0.630.310.52-0.060.02-0.38-0.210.66-0.440.69
-0.36-0.42-0.27-0.72-0.29-0.36-0.280.06-0.010.130.39-0.39-0.34-0.060.48-0.31-0.47-0.26-0.53-0.29-0.31-0.120.2-0.270.02-0.4-0.190.33-0.120.29
0.190.6-0.14-0.160.58-0.070.140.030.2-0.18-0.770.530.420.52-0.770.330.320.330.710.110.76-0.11-0.740.5-0.38-0.40.5-0.57-0.08-0.53
0.290.30.170.030.240.20.150.110.24-0.03-0.330.370.510.51-0.370.30.320.70.410.180.39-0.01-0.050.81-0.21-0.190.5-0.030.3-0.19
0.26-0.290.450.31-0.050.40.070.180.01-0.010.75-0.02-0.120.00.840.110.150.35-0.130.24-0.580.220.80.040.660.33-0.57-0.030.10.82
0.040.110.180.1-0.180.20.02-0.030.76-0.01-0.13-0.120.58-0.36-0.110.02-0.29-0.1-0.040.040.2-0.090.280.1-0.44-0.12-0.080.30.1-0.11
0.22-0.10.290.20.090.270.150.1-0.010.050.540.1-0.160.010.90.130.180.220.00.22-0.560.140.6-0.120.690.29-0.53-0.190.82-0.11
Click cells to compare fundamentals
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Competition

Novartis Net Invested Capital

Net Invested Capital

73.35 Billion

At this time, Novartis' Net Invested Capital is comparatively stable compared to the past year.
Based on the company's disclosures, Novartis AG ADR has a Working Capital of 4.09 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is 176.76% lower than that of the firm.

Novartis Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.
Novartis is currently under evaluation in working capital category among related companies.

Novartis Fundamentals

About Novartis Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Net Working Capital4.1 B5.7 B
Change In Working Capital-369 M-350.6 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out Novartis Piotroski F Score and Novartis Altman Z Score analysis.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
4.987
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
22.467
Quarterly Revenue Growth
0.074
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.